levels in rats with no La in their diet than in those given adenine with La (Figure 3A in [1] ). These results can only be due to contamination either in the animal facility or during sample analysis. Toxicology studies require meticulous attention to separation of laboratory animals and samples, far more than is necessary for other laboratory studies. As was pointed out in the correspondence of Rambeck [4] , the high lung La levels that were reported by Lacour et al. may very well represent La that was inhaled from the powdered diet. Furthermore, the plasma phosphorus levels were markedly reduced by La in both models of CRF used by Lacour et al. [1] and the decreased serum phosphorus may very well have contributed to the reduction in organ weight that they found. To exclude phosphorus depletion as a cause for any apparent changes in organ weight, we introduced a control group with adenine-induced renal failure fed an adenine-low phosphorus diet for the last four weeks of the study.
In summary, ingested La did not cause a reduction in liver weight in our study nor any hepatotoxicity in ours and other studies as well as in patient studies. Long-term application of lepirudin on chronic haemodialysis over 34 months after heparin-induced thrombocytopenia
Sir, The development of heparin-induced thrombocytopenia (HIT) is a well-known complication of heparin therapy.
Once the syndrome occurs and is recognized, it is essential to immediately avoid any sources of heparin. If anticoagulation is still required, other anti-coagulants should be considered such as lepirudin, argatroban, danaparoid or fondaparinux in the acute phase usually followed by warfarin after normalization of the thrombocytes.
A 75-year-old hypertensive male Caucasian with preendstage renal disease was admitted to this hospital because of acute aortic dissection. The aorta was successfully replaced by a composite graft at the University Hospital of Zu¨rich. Post-operatively, the patient was anuric and continuous venovenous haemofiltration (CVVH) was installed with unfractionated heparin as anti-coagulant. The patient was transferred back to this hospital. HIT II was diagnosed based on a drop of the platelet count from 190 to 44 Â 10 9 /ml on day 7 in the absence of alternative explanations and confirmed by ELISA (Asserachrom HPIA, Fa Stago/ Roche). CVVH was continued initially without any anticoagulant (Fresenius Filter F6, no blood dilution, flow 250 ml/min). Haemodialysis was initiated on day 14 postoperatively with a low-flux dialyser (Hemoflow F6, Fresenius Medical Care) using lepirudin to achieve adequate anticoagulation. Lepirudin is an irreversible thrombin inhibitor whereas heparin binds to anti-thrombin which inactivates thrombin and FXa. We chose lepirudin because of already existing short and intermediate-time experience in haemodialysis-patients [1,2]. Lepirudin was given as an intravenous bolus immediately before dialysis (0.025 mg/kg body weight, total dose: 3.5 mg). The monitoring was performed by the activated partial thromboplastin time (aPTT), in analogy to the HAT-Studies [3] by the thrombin time (TT) (5 NIH-E/ml), by the lepirudin concentration [4] , and by the observation of eventual clotting in the venous chamber.
For the first four haemodialysis sessions, we used a lowflux dialyser (Fresenius Hemoflow F6). After the introduction of a high flux filter (CT 190, Baxter) a large clot built up in the venous chamber. We therefore increased the lepirudin dose before the dialysis to 0.07 mg/kg bw (¼5 mg), but the clot still formed repeatedly. With a further increase to 7 mg with dose splitting [two-thirds (4.5 mg) at the beginning and one-third (2.5 mg) after 1.5 h of dialysis], the problem was solved. We interpreted this as an increased initial extraction by the high-flux filter which correlates with the findings on membrane permability by other authors [5, 6] . For 34 months now, no further changes of the lepirudin dose were required. Anti-lepirudin antibodies were negative 10 months after the introduction of haemodialysis (methods: 6, 7). The use of lepirudin may be associated with the development of antihirudin antibodies in 45-74% of the patients [7] . These antibodies may lead to a prolonged functional halflife and to an increased anticoagulatory effect.
Lepirudin is eliminated from the organism exclusively by the kidneys and its plasma levels correlate linearly with the creatinin clearance [4] . At low plasma concentrations, anticoagulation monitoring seems possible with aPTT, but the linear relation is lost at higher concentrations [8] . The ecarin clotting time is proposed for lepirudin monitoring at higher concentrations [4, 9] .
We conclude that long-term application of lepirudin at split-low dose in HIT-patients on haemodialysis represents an effective and safe alternative.
Conflict of interest statement. None declared. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation Sir, Chronic myeloid leukaemia (CML) is a rare malignant complication in solid organ recipients [1] . Imatinib mesylate, a potent inhibitor of the Bcr-Abl protein tyrosine kinase encoded by the Philadelphia chromosome, has proven to be effective and is currently approved for first-line treatment of CML. The goal of imatinib treatment is to achieve not only cytogenetic remission, but also complete molecular remission, as defined by undetectable blood levels of BCR-ABL transcripts using quantitative polymerase chain reaction (PCR). Although cytogenetic remission of de novo CML with imatinib therapy has been recently reported in a renal transplant patient [2], the efficiency and tolerance of the strategy in this particular population remains to be confirmed. In July 2000, a 53-year-old Caribbean woman received a cadaveric kidney transplant for end-stage renal failure secondary to diabetic nephropathy. Immunosuppressive treatment consisted of anti-thymocyte globulin, ciclosporin A (CsA), mycophenolate mofetil (MMF) and steroids. In August 2002, she developed CML (leukocytosis 28.6 Â 10 9 /l, Table 1 ) confirmed by cytogenetic analysis of bone marrow smears. Imatinib was started at conventional dose of 400 mg daily, while CsA and MMF were maintained. Seven weeks later, imatinib was transiently discontinued because of neutropenia, and resumed at 300 mg daily with a 25% reduction in CsA dose. Worsening of glycaemic control required combined oral antidiabetic and insulin therapy. In April 2003, MMF was switched to azathioprine because of chronic diarrhoea. At this time, the patient had achieved complete cytogenetic and molecular response, with bcr-abl/abl ratio <0.01% by PCR, which was maintained at last follow-up (Table 1) . In January 2004, a breast cancer was diagnosed. A complete remission was obtained with mastectomy, radiotherapy and hormonal treatment. An allograft biopsy, performed because of progressive degradation of renal function (creatininaemia 203 mmol/l, without proteinuria), revealed border-line cellular rejection and grade I chronic allograft nephropathy without peritubular capillaries C4d deposits, but diffuse staining of glomerular and tubular basement membranes with anti-gamma, anti-kappa, anti-lambda and anti-albumin conjugates, as expected because of diabetes. Arterial and arteriolar sections appeared nearly normal without fibrous endarteritis, nor subendothelial hyalinosis (Figure 1 ).
In conclusion, we report the first case of sustained molecular remission of CML with first line prolonged imatinib therapy in a renal allograft recipient. With slight reduction of CsA and imatimib doses, both substrates of CYP3A4, tolerance of imatimib therapy was good. That our patient required intensification in antidiabetic therapy does not support recent data suggesting beneficial effects of imatinib on glycaemic and lipid control [3, 4] . Imatinib is also a selective PDGF-R tyrosine kinase inhibitor with vascular antiproliferative properties, including prevention of chronic allograft nephropathy [5] , or reduction of heart allograft arteriosclerosis [6] in animals. Although a beneficial role of imatimib in the prevention of chronic renal allograft vasculopathy remains unproven, imatimib was a safe therapy in our patient, with almost normal vascular sections despite grade I chronic allograft nephropathy on a late kidney biopsy. 
